Article Trunk



Primary Immune Deficiency Diseases Therapeutics Pipeline Analysis 2018

07.25.2019 · Posted in Health Articles, Health Care Articles

Primary immune deficiency diseases are rare and genetic disorders, that are characterized by an impaired immune system. Some of the symptoms observed in the patients with these diseases are blood disorders, autoimmune disorders, recurrent pneumonia, inflammation of internal organs, and digestive problems. 

Download the sample report @ https://www.pharmaproff.com/request-sample/1051

Primary immune deficiency diseases can occur due to B-cell deficiencies, T-cell deficiencies, defective phagocytes, combination of B- and T-cell deficiencies, and complement deficiencies. 

Get the detailed analysis @ https://www.pharmaproff.com/report/primary-immune-deficiency-diseases-therapeutics-pipeline-analysis

The only risk factor associated with this disease is family history. GigaGen Inc. is in the process of developing recombinant intravenous immunoglobulin (rIVIG) for the treatment of primary immune deficiency diseases. X4 Pharmaceuticals Inc. is in the process of developing X4P-001-RD as a CXCR4 receptor antagonist for the treatment this disease. Orchard Therapeutics Ltd. is also engaged in the pipeline for this disorder.

Comments are closed